AstraZeneca has entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s ...

Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alteogen, the top corporation by market capitalization on the KOSDAQ, is experiencing a drop of over 9%. As of 2:32 p.m. on the 20th, Alteogen is trading at 381,000 won, down 38,000 won (9.07% ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

As global trade tensions escalate, Asian markets have faced significant volatility, with investors closely monitoring the economic impacts of ongoing tariff disputes. Amidst this uncertainty, ...

Merck plans to launch US subcutaneous version of Keytruda on October 1 Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...